T2–T3HAMPharmaceuticals & HealthcareAdvanced Materials
Reaction pathway / transition-state modeling
Model reaction pathways — value high, native fit narrow.
Sector
Chemistry / pharma
Likely buyer
Chemical & pharma R&D
Hardware gate
Reduced models near-term
Taxonomy
capability-absent × enabling
No live demo yet — narrow native window; requires careful reduction. The paradigm-honest position: this use case is demonstrated with crossover analysis, not theater.
GTM talk track
'Where it reduces to the native class, we simulate; otherwise classical.'
OGSM — product operating frame
Objective
Scope a reducible pathway.
Goals
- One group defines a model
Strategies
- Reduce carefully
Measures
- Pathways modeled
OBR — outcome-based roadmap
| Horizon | Outcome we create | Buyer behavior change | Result we measure |
|---|---|---|---|
| Now | Group sees a reduced model | Prospect runs the emulated demo on their own instance data | Booked QPU-time evaluation or paid pilot |
| Next | Group benchmarks | Prospect co-designs a scoped benchmark against their incumbent solver | Documented crossover curve; expansion to production instances |
| Later | Group revisits at scale | Prospect standardizes on the workflow or buys an on-prem system | Recurring QPU consumption / system sale; reference case |
Fit notes (honesty gate)
Value high; native window narrow.
Ready to run this on real hardware?
Emulation-verified today — the same program runs on a Pasqal QPU unchanged.